Invokana diabetes drug faces Canadian class-action lawsuit
Jack Julian is a data journalist in the Halifax newsroom. This is a new position, and he's excited about it. He likes surprises in his stories. Email: [email protected] Twitter: @jackjulian
The diabetes drug Invokana, recently adopted by Nova Scotia's pharmacare program, is now the subject of a national class-action lawsuit.
Court documents filed at the Ontario Superior Court of Justice allege the drug can cause kidney damage or death in some of those who take it.
"We believe that Invokana is a very risky drug for kidney failure, and that the medical profession and users of the drug should be alerted to the dangers and consider very carefully whether they continue on Invokana," said Tony Merchant, the Regina-based lawyer whose company, Merchant Law Group, is behind the lawsuit.
The class action has not been certified. Merchant said he expects that to happen in the next six to seven months.
None of the allegations have been proven in court.
Under Nova Scotia law, the action must first be certified as a class action before it can proceed.
Invokana was created by the multinational drug company Janssen Inc., and was approved by Health Canada in May 2014.
The Nova Scotia government added Invokana to the province's pharmacare formulary on Sept. 1, the third province to do so after Ontario and Quebec.
Scarborough woman at centre of lawsuit
Invokana isn't the only diabetes drug before the Canadian courts.
Lawyers in Halifax argued Tuesday in Nova Scotia Supreme Court for the certification of a class action suit against the drug Avandia from GlaxoSmithKline. Avandia is an insulin s Continue reading